4D Molecular Therapeutics, Inc.(FDMT)Company Profile & BusinessNASDAQ
Business, leadership and ownership
Company Profile
Business overview, scale, and footprint
Business Overview
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for 4D Molecular Therapeutics, Inc. (FDMT) between Nov 17, 2025 and Oct 16, 2026 consists of 25 total transactions. Among these, company executives and board members conducted 0 buys (totaling 0 shares) and 25 sells (totaling 427,549 shares). This activity resulted in a net change of -427,549 shares, reflecting net selling pressure with an estimated net sales value of $5.35M.
25 insider transactions found. Showing 10 of 25 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| Bizily Scott | Chief Legal Officer | -1,635 | $12.84 | Oct 16, 2026 |
| Kirn David | President and Chief Executive Officer | -58,061 | $12.92 | Oct 5, 2026 |
| Kirn David | President and Chief Executive Officer | -272 | $13.61 | Oct 5, 2026 |
| Bizily Scott | Chief Legal Officer | -1,635 | $13.65 | Sep 16, 2026 |
| Kirn David | President and Chief Executive Officer | -58,333 | $13.90 | Sep 14, 2026 |
| Bizily Scott | Chief Legal Officer | -584 | $14.00 | Sep 1, 2026 |
| Kirn David | President and Chief Executive Officer | -43,149 | $15.36 | Aug 19, 2026 |
| Kirn David | President and Chief Executive Officer | -25,927 | $16.42 | Aug 19, 2026 |
| Bizily Scott | Chief Legal Officer | -1,635 | $12.20 | Aug 17, 2026 |
| Bizily Scott | Chief Legal Officer | -1,635 | $12.00 | Aug 13, 2026 |
Explore More Analysis for FDMT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.